NEWS | July 26, 2016

De Vere White to serve on prestigious NIH panel


Ralph de Vere White, who retired in June as director of the UC Davis Comprehensive Cancer Center, has been named to a key committee at the National Institutes of Health (NIH).

Ralph de Vere White Ralph de Vere White

For a two-year term, which began July 1, de Vere White will serve on the NIH Center for Scientific Review’s Developmental Therapeutics Study Section, tasked with reviewing research applications in the field of cancer therapeutics.

Candidates are chosen based on dedication to and achievement in their field. Members must have numerous high-quality research accomplishments and publications and must participate in other scientific activities.

In a letter to Julie A. Freischlag, UC Davis vice chancellor for Human Health Sciences and dean of the School of Medicine, Richard Nakamura, director of the Center for Scientific Review said the position also requires “mature judgment and objectivity, as well as the ability to work effectively in a group, qualities we believe Dr. de Vere White will bring to this important task.”

As cancer center director, de Vere White led and contributed to significant leading-edge research, including in the development of treatments for advanced prostate and bladder cancer, which prepared him well for his role on the study section.

The Developmental Therapeutics Study Section focuses on the development of research that offers promising opportunities for translation into medical practice. The cancer center has long emphasized bringing promising new treatments form the laboratory bench to the bedside and development of clinician-scientists to conduct translational research.

De Vere White said he looks forward to the opportunity to serve the cancer community in a national capacity for the NIH.

“I am so pleased to be asked to serve on this important review section,” said de Vere White, who will return this fall to UC Davis part-time in a research capacity. “This is an exciting time for cancer discoveries, and I look forward to being part of seeing those discoveries become real solutions for our patients.”